key: cord-0290894-ii7pinci
authors: Freire Rodrigues, E.; Moreno, J.; Pinto Leite, P.; Nunes, B.; Gomes, J. P.; Ferreira, R.; Isidro, J.; Borges, V.; Vieira, L.; Duarte, S.; Sousa, C.; Almeida, J. P.; Menezes, L.; Vaz, D.; Leite, A.; PERALTA SANTOS, A.
title: B.1.617.2 SARS-CoV-2 (Delta) variant is associated with increased risk of hospitalization and death compared with B.1.1.7 SARS-CoV-2 (Alpha) variant
date: 2022-01-23
journal: nan
DOI: 10.1101/2022.01.21.22268602
sha: a68313a0452f6465e918b2f27b82e08dcbdd7542
doc_id: 290894
cord_uid: ii7pinci

Introduction The B.1.617.2 variant (Delta) was associated with increased transmissibility and lower vaccine effectiveness than the B.1.1.7 variant (Alpha). However, the effect of the B.1.617.2 variant on disease severity remains unclear. This study aims to assess whether infection with the B.1.617.2 variant was associated with a higher risk of serious illness, compared with other co-circulating variants, measured through hospitalization and death by COVID-19 in Portugal. Methods We conducted a matched cohort study in adult individuals diagnosed with SARS-CoV-2/COVID-19 infection between March 29 and August 1, 2021. Cases were individuals with a positive PCR test notified to the surveillance system. SARS-CoV-2 variants were classified first by genomic sequencing (WGS) and, if this information was unavailable, by detecting the S gene target failure. Delta (B.1.617.2) and Alpha (B.1.1.7) cases were matched on the week of diagnosis at a 1 to k ratio (k being the maximum number of unexposed available in that week) to maximize the inclusion of unexposed, using the nearest-neighbor algorithm. The hazard risk and 95% confidence intervals of hospitalization and death among those infected with the Delta (B.1.617.2) variant vs. Alpha (B.1.1.7) was estimated using a Cox proportional hazards model, adjusting for confounding for sex, age, and vaccination status. Results A total of 2,778 cases were included in the study. Of the total, 1 742 (68%) were identified as B.1.617.2 variant cases and 3 629 (32%) as B.1.1.7 variant. Within the B.1.1.7 variant cases 106 (2.9%) were hospitalized, and 110 (6.3%) within the B.1.617.2 variant cases. A total of 29 deaths were reported, 8 (0.2%) in patients infected with B.1.1.7 variant and 21 (1.2%) in patients with the B.1.617.2 variant. The confounding adjusted risk of hospitalization, in persons infected with the B.1.617.2 variant was 2.44 (95%CI 1.85; 3.20) times higher than the risk of hospitalization among B.1.1.7 variant cases, and the confounding-adjusted risk of death for B.1.617.2 variant cases was 5.20 (95%CI 2.20; 12.29) times higher than the risk of death in patients infected by B.1.1.7 variant. Conclusion The B.1.617.2 variant is associated with an increased risk of hospitalization and death compared with the B.1.1.7 variant.

The B.1.617.2 variant (Delta) was associated with increased transmissibility and lower vaccine effectiveness than the B.1.1.7 variant (Alpha). However, the effect of the B.1.617.2 variant on disease severity remains unclear.

This study aims to assess whether infection with the B.1.617.2 variant was associated with a higher risk of serious illness, compared with other co-circulating variants, measured through hospitalization and death by in Portugal.

We conducted a matched cohort study in adult individuals diagnosed with SARS-CoV-2/COVID-19 infection 3

The adaptation processes of SARS-CoV-2, characterized by different mutations, are a challenge to contain the pandemic impact on health systems and population health. Most mutations have little influence on the virus' ability to cause disease. However, the estimated mutation rate of SARS-CoV-2 is more than four times higher than the seasonal Influenza HA1 subunit (1) . Depending on where these mutations are in the genetic chain, they may change the virus' properties. When mutations yield a selective advantage by increasing the transmissibility or the ability to evade the host immune response or increasing disease severity, they are classified as Variants of Concern (VOC) (2).

The B.1.1.7 SARS-CoV-2 (also known as Alpha variant) is characterized by several spike protein changes being the deletion 69-70 the one responsible for changes in S-gene detection on RT-PCR assays (3, 4) . Since its first detection, the spread of this variant to the UE/EEA countries was fast, becoming the most prevalent variant in many countries as Portugal, in the first months of 2021 (4). Vaccines are currently the best solution to control the impact of the SARS-CoV-2 pandemic and reduce the burden on healthcare institutions' capacity and mortality (6) . Nevertheless, the emergence of new SARS-CoV-2 variants with increased immune evasion may reduce the vaccine effectiveness (7) and cause stress on health systems. The Omicron VOC emergence in November 2021 (8) is a testament to the vaccine effectiveness (9, 10) .

Vaccine effectiveness studies have shown that current vaccines effectively prevent symptomatic infection and disease that leads to hospitalization and reduce case-fatality rate (11 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22268602 doi: medRxiv preprint

We designed a matched cohort study to assess the risk of hospitalization and the risk of death of the individuals 

We used two different methods to identify which samples were B. classification from WGS and SGTF), we accepted the WGS result as final due to higher accuracy (17) .

We defined hospitalization as any admission to a public hospital with the primary diagnosis being COVID-19 (ICD- A COVID-19 death was defined as any record of death on the national Death Certificate Information System (SICO) with COVID-19 as the primary cause of death (ICD-10 code U.071) according to the WHO classification (18) . SICO platform allows the issuance of a death certificate for each person who dies in Portugal.

We obtained the COVID-19 vaccination status through the electronic national vaccination register (VACINAS). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22268602 doi: medRxiv preprint surveillance system SINAVE and was extracted from it. Age categories were created accordingly to the functional form of the variable based on the Martingale residuals.

We used data from different databases: SINAVE is the national epidemiological and laboratory surveillance platform for SARS-CoV-2 infections, SICO the electronic death certificate platform, VACINAS the electronic vaccination platform, BDMH the hospital admission platform of the National Health System, data from sequencing was provided by the National Institute of Health. Data were extracted on September 17, 2021.

Record-linkage was performed using a unique identifier (national health service number) to exclude duplicates.

Duplicates or suspected reinfection were excluded.

Matching was performed based on the week of SARS-CoV-2 infection diagnosis using variable ratio matching, at a ratio of 1 to k, where k is the maximum number of B.1.1.7 cases available on the respective week. Additionally, to optimize the use of controls in periods of B.1.617.2 dominance that resulted in a scarcity of controls for matching, we used a nearest-neighbor algorithm provided with the "Matchit"(19) CRAN package.

We compared the characteristics of SARS-CoV-2 cases using central tendency and dispersion measures for continuous variables and absolute and relative frequencies for categorical variables. The B.1.617.2 cases were considered exposed, while B.1.1.7 cases were considered the reference group.

The confounding-adjusted hazard ratio of hospitalization and death, with 95% confidence intervals (CI), was calculated using a proportional hazards Cox model, adjusted for sex, age, and vaccination status (equation 1). To check if the vaccination status was an effect modifier of the association between variant and severity, we added an interaction term between the variant and vaccination status to the model. We stratified the analysis by unvaccinated and vaccinated (partial and complete). We tested the proportionality of risk assumptions using is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22268602 doi: medRxiv preprint visual inspection of scaled Schoenfeld residuals (20) . We used the survival package to do the proportional hazards Cox model (21) .

Due to the nature of the outcomes and their national availability, our analysis assumed a type I right censoring, thus using a fixed end of follow-up date defined as August 31, 2021. Analyses were based on a complete case analysis. All tests were two-sided, and a P-value < .05 was considered statistically significant. All statistical analyses were performed on R® using R Studio version 1.4 (22) .

The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22268602 doi: medRxiv preprint Most of the study participants were women (51.7%), the mean age was 41.9 (SD=15.8) years (supplementary material S1), and unvaccinated (82.3%). The mean length of stay in the hospital was 10 (SD=8.8) days. The characteristics of the patients at baseline were balanced between the groups (Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

The crude cumulative mortality probability at the 30 th day after a diagnosis of SARS-CoV-2 after the COVID-19 diagnosis the cumulative mortality probability was 0.2% (95%CI 0.1% to 0.4%) for B. When we tested for the interaction between the variant and the vaccination status, the HR coefficients were not statistically significant for the death outcome, however, we stratified to compare estimates. Stratified by . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. B.1.617.2, Delta versus B.1.1.7 We found no significant violation of the proportionality of hazards assumptions (supplement materials for more information).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. Previous studies have reported similar results for the risk of hospitalization using diverse study designs. We report very similar estimates of the hazard ratio of hospitalization, adjusted HR of 2.44 (95%CI 1.85 to 3.20) compared to the England cohort study (14) HR 2.26 (IC95% 1.32 to 3.89) using samples with lineage identification through WGS. Furthermore, our results are also in line with the findings of the Scotland study (15) that assessed hospitalization risk with samples with lineage identification through TGSF, but a higher magnitude was found in our study HR 1.85 (95%CI: 1.39 to 2.47). The similitude between the relative risk of hospitalization estimated between our study and the England cohort study strengthens the evidence of the increased risk by the Delta variant when compared with Alpha variant cases.

To the best of our knowledge, we provide for the first time estimates of HR for mortality comparing Delta We report a statistically significant interaction between variant and vaccination status for the hospitalization outcome. Stratified by vaccination status we found that the risk for hospitalization and death is consistently higher for Delta compared with Alpha, however the risk has a higher magnitude for unvaccinated participants.

Moreover, for vaccinated participants the precision was too low to determine whether the risks of hospitalization were higher or similar for participants with the delta variant compared with participants with the alpha variant. This is consistent with other studies that reported similar findings (14) . The risk of death is consistently higher for Delta in unvaccinated and vaccinated participants, and the interaction between variant and vaccination status was not significant.

We designed a retrospective cohort matched by the week of diagnosis design to minimize the effect of time and time-associated cofounders on risk estimates such as, e.g., bed occupancy, availability of hospitals for further admissions or vaccination coverage. Even with a variable delta to alpha ratio approach for comparator selection, this design reduced the sample size. That reduced our power, particularly for rare events, as in the mortality analysis and stratified analysis by vaccination status. However, this approach minimized biases and provided more robustness to our estimates by mitigating the effect of time-dependent confounders. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Our study benefits extensively from the secondary use of administrative and health-related data sources. These systems (SARS-CoV-2 cases, hospitalization, death, vaccination registers) and unique identifiers allow researchers to answer complex investigation questions in shorter periods and fewer resources. However, secondary use of administrative data encompasses several limitations. First and foremost, hospital admission data can have delays due to coding processes, which would significantly affect participants diagnosed closer to the end of the study period. As the B.1.617.2 variant has become dominant halfway from the end study, it can be argued that this delay would lead to an underestimation of the number of events in this group and by consequence an underestimation of the HR of death and hospitalization. We have mitigated this factor by extracting data on hospital admissions almost two months after the end of the study period.

The selection of samples for WGS and SGTF was independent of the VOC type and severity, e.g., hospitalization or death, making the risk of differential selection bias residual. Our study sample showed a skewness towards younger ages, and this may be explained by the fact that our cases were collected mainly through ambulatory laboratories. At the same time, older (80+) individuals are expected to be more frequently diagnosed by hospital laboratories. While the cumulative risk of hospitalization and death could be underestimated, it is unlikely that the age distribution in the study would bias the variant HR estimates.

We cannot exclude residual confounding in the study, our study did not account comorbidities. Patients infected with Delta variant for the same age could be sicker (immunocompromised, higher burden of comorbidities) and that affected the risk of hospitalization and death disproportionately for Delta patients. Other variables, such as such as place of residence are unlikely to be confounders. On the one hand the probability of differences by variant is low, as the B.1.617.2 variant became dominant similarly throughout the country. On the other hand differences in hospital admission by region due to access conditions is not expected as Portugal has a mainly national healthcare system with good regional coverage and regional availability (25) .

Additionally, there was no information available on the presence and type of symptoms at the time of diagnosis.

As such, we cannot describe the proportion of symptomatic and asymptomatic infections between patients infected with B.1.1.7 and with B.1.617.2. However, the risk of hospitalization and death is not influenced by the distribution and quality of symptoms and is a mediator effect and not a confounder. All the patients with symptoms and meeting the criteria for hospitalization in national guidelines should be hospitalized.

Misclassification of variant is a potential limitation because we used S gene no amplification to identify the variant. This method has been used before, mainly in the Scottish study (15), and misclassification is minimized because we used sequencing data whenever present. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22268602 doi: medRxiv preprint

This study supports the hypothesis of higher severity of Delta variant. We report a risk of COVID-19 hospitalization that was double (HR 2.44, 95%CI 1.85 to 3.20) for participants infected with the Delta variant when compared to the Alpha variant and risk of death in the Delta variant participants is five times (HR 5.20 95%CI 2.20 to 12.29) than for Alpha participants.

For unvaccinated patients, the HR risk for hospitalization and death is consistently higher for Delta than Alpha.

However, we cannot exclude that the risk of hospitalization in vaccinated patients could be identical between patients infected with Alpha and Delta, HR 1.59 (95%CI 0.94 to 2.69). The risk of death is still higher for Delta than Alpha, in vaccinated patients HR 3.39 (95%CI 1.06 to 10.84).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22268602 doi: medRxiv preprint

Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. Available at SSRN 3932602

Geographic and genomic distribution of SARS-CoV-2 mutations

Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England

Tracking SARS-CoV-2 VOC 202012/01 (lineage B. 1.1. 7) dissemination in Portugal: insights from nationwide RT-PCR Spike gene drop out data

SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants

Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants. Emerging infectious diseases

Sequence analysis of the Emerging Sars-CoV-2 Variant Omicron in South Africa

Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern. medRxiv

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet

mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal

Vaccine effectiveness against infection with the Delta (B. 1.617. 2) variant, Norway

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2)

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet

No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway

Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England

Medical certification of cause of death for COVID-19

Package 'MatchIt'. Version

Proportional hazards tests and diagnostics based on weighted residuals

R survival package

RStudio: a platform-independent IDE for R and Sweave

Increased lung cell entry of B. 1.617. 2 and evasion of antibodies induced by infection and BNT162b2 vaccination

B. 1.617. 2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination

Portugal: Health system review